ClinicalTrials.gg
Active, not recruitingNCT06290128MOBILIZEUpdated Aug 10, 2026

A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work

A Phase 3 interventional study of Riliprubart and Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy and Polyneuropathy, Inflammatory Demyelinating, Chronic, sponsored by Sanofi. Active, not recruiting at 132 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
109
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 55 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in United States — 20 open to participants now, 25 under way, 10 of them phase 3. Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States.

Enrollment
14th of 42
109 · median 74
Started
2024
with 2 others
Phase 3
15 of 55
8 open now
Primary completion
2026-06
later than 1 of 24 live
Registered
36th of 55
by date
Lead sponsor
4 of 55
Sanofi

Among the 55 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in United States, this one is the 14th largest by enrollment of the 42 interventional ones that give a count, is one of 3 that started in 2024, is one of 15 in phase 3, reaches primary completion later than 1 of the 24 other live ones, and was the 36th registered.

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

137 studies on the registry are indexed under Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; 50 are open to participants now.

Browse Polyradiculoneuropathy, Chronic Inflammatory Demyelinating studies →

Open to participants now

20 of the 55 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 36 Polyradiculoneuropathy, Chronic Inflammatory Demyelinating studies recruiting now, 24 (67%) set no upper age limit and 9 (25%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate efficacy of riliprubart compared to placebo in adult participants with CIDP whose disease is refractory to standard of care. The study duration will be for a maximum of 111 weeks including screening, treatment phases, and follow-up.

03

Conditions studied

  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy
  • Polyneuropathy, Inflammatory Demyelinating, Chronic

Keywords

  • Autoimmune Diseases, Neurologic
  • Autoimmune Disorders, Nervous System
  • Peripheral Nerves Disease
  • Nervous System Diseases
  • Neurologic Disorders
  • Neurological Disorders
  • Complement Inhibitor
  • Complement Inhibitors
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants are eligible to be included in the study only if all of the following criteria apply:

  • Participant must have CIDP or possible CIDP criteria, based on European Academy of Neurology (EAN)/ Peripheral Nerve Society (PNS) Task Force CIDP guidelines, second revision (2021).
  • Participant must have either typical CIDP, or one of the following two CIDP variants: motor CIDP, multifocal CIDP (also known as Lewis Sumner Syndrome). Diagnosis must be confirmed by the adjudication committee.
  • Participant must be to either immunoglobulin therapy or therapy, as defined below.

    • Immunoglobulin-refractory subgroup: Historic evidence of failure or inadequate response to immunoglobulin therapy prior to screening
    • Corticosteroid-refractory subgroup: Historic evidence of failure or inadequate response to corticosteroid therapy prior to screening
  • Participant has an INCAT score of 2 to 9
  • Any allowed drugs (azathioprine, cyclosporine, or mycophenolate mofetil) have been taken for ≥6 months
  • Participant may be receiving low-dose oral corticosteroids (≤20 mg/day of prednisone or equivalent)
  • Participant must have active disease, defined by a CIDP disease activity score (CDAS) of ≥ 2 points at Screening
  • Participant must have documented vaccinations against encapsulated bacterial pathogens given within 5 years prior to Day 1 or initiated a minimum of 14 days prior to first dose of study intervention
  • for sexually active male or female participants; not pregnant or breastfeeding; no sperm donating for male participant
  • A body weight at Screening of 35 kg to 154 kg (77 to 340 lbs), inclusive

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • Polyneuropathy of other causes, including but not limited to: acute demyelinating polyneuropathies (eg, Guillain-Barré syndrome), hereditary demyelinating neuropathies, neuropathies secondary to infection or systemic disease, diabetic neuropathy, drug- or toxin-induced neuropathies, multifocal motor neuropathy, polyneuropathy related to Immunoglobulin M (IgM) monoclonal gammopathy, POEMS syndrome, and lumbosacral radiculoplexus neuropathy.
  • Sensory CIDP, Distal CIDP and focal CIDP variants.
  • Any other neurological or systemic disease that can cause symptoms and signs interfering with treatment or outcome assessments
  • Poorly controlled diabetes
  • Serious infections requiring hospitalization within 30 days prior to Screening and any active infection requiring antimicrobial treatment during screening or presence of a condition that may predispose the participant to increased risk of infection (eg, medical history such as known immunodeficiency or history of recurrent infections)
  • Clinical diagnosis of Systemic Lupus Erythematosus (SLE) or family history of SLE. For a participant with an antinuclear antibody (ANA) titer ≥1:160 and a positive anti-double-stranded DNA (anti-dsDNA) at Screening, SLE diagnosis must be ruled out prior to enrollment.
  • Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the Investigator, contraindicates participation in the study. Specifically, history of any reaction to riliprubart or its components or of a severe allergic or anaphylactic reaction to any humanized or murine monoclonal antibody.
  • Any other medical history or ongoing medical condition (as determined by the Investigator at Screening) that might impact benefit-risk assessment, jeopardize the safety of the participant, or compromise the quality of the data collected in this study; or history or presence of other significant concomitant illness that would adversely affect participation in this study, per Investigator's judgment.
  • Documented history of attempted suicide over the 6 months prior to the Screening visit, presence of suicidal ideation of category 4 or 5 on C-SSRS during screening, OR if in the Investigator's judgment, the participant is at risk for a suicide attempt.
  • Evidence of CIDP worsening within the 6 weeks following a prior vaccination that, in the opinion of the Investigator, constituted a relapse
  • Recent or planned major surgery that could confound the results of the trial or put the participant at undue risk
  • Participant has recently received immunoglobulins (IVIg or SCIg)
  • Recent treatment with plasma exchange
  • Prior treatment with riliprubart
  • Prior treatment with (any time) with highly /chemotherapeutic medications with sustained effects, eg, mitoxantrone, alemtuzumab, cladribine
  • Prior treatment (any time) with total lymphoid irradiation or bone marrow transplantation
  • Prior treatment with B-cell-depleting agents such as rituximab within 6 months
  • Use of any specific complement system inhibitor (eg, eculizumab) within 12 weeks or 5 times the half-life of the product, whichever is longer
  • Treatment within 6 months prior to dosing with immunosuppressive/ chemotherapeutic medications, such as cyclophosphamide, methotrexate, tacrolimus, interferon, or tumor necrosis factor (TNF)-α inhibitors. Certain immunosuppressants commonly used in CIDP (azathioprine, cyclosporine, or mycophenolate mofetil) are allowed, as indicated under inclusion criterion.
  • Any vaccination received within 28 days prior to dosing (with few exceptions to be confirmed at screening)
  • Participation in another clinical trial with an drug or receipt of an investigational product within 12 weeks or 5 times the half-life of the product, whichever is longer, prior to Screening
  • Any screening laboratory values outside normal limits or abnormal considered in the Investigator's judgment to be clinically significant in the context of this trial
  • Positive result of any of the following tests:

    • surface antigen (HBsAg).
    • Anti-hepatitis B core antibodies (anti-HBc Ab) (unless anti-hepatitis B surface antibodies [anti-HBs Ab] are also positive, indicating natural immunity).
    • Anti- virus (anti-HCV) antibodies (participants with positive hepatitis C antibody due to prior resolved disease can be enrolled, only if a confirmatory negative Hepatitis RNA test is obtained).
    • Anti- 1 and 2 (anti-HIV1 and anti-HIV2) antibodies.
  • Pregnancy, defined as a positive result of a highly sensitive urine or serum pregnancy test, or lactation
  • Accommodation in an institution because of regulatory or legal order; eg, imprisoned or legally institutionalized
  • Participant not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions, or potential risk for noncompliance to study procedures
  • Participants are employees at the clinical study site or other individuals directly involved in the conduct of the study, or immediate family member of such individuals
  • Any country related specific regulation that would prevent the participant from entering the study
  • Recent treatment with efgartigimod

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
109 participants (actual)

Study arms

  • Experimental
    Riliprubart Arm

    Riliprubart for 24 weeks followed by open-label extension phase with riliprubart for 24 weeks

    Drug: Riliprubart · Drug: Placebo

  • Placebo comparator
    Placebo Arm

    Placebo for 24 weeks followed by open-label extension phase with riliprubart for 24 weeks

    Drug: Riliprubart · Drug: Placebo

Interventions

  • Pharmaceutical form: Solution Route of administration: IV Infusion

    Also known as: SAR445088

  • DrugPlacebo

    Pharmaceutical form: Solution Route of administration: IV Infusion

  • Pharmaceutical form: Solution Route of administration: SC Injection

    Also known as: SAR445088

  • DrugPlacebo

    Pharmaceutical form: Solution Route of administration: SC Injection

06

What researchers measure

Primary outcomes

  1. Percentage of participants experiencing a response

    A response is defined as a decrease of ≥1 point from baseline in adjusted INCAT disability score at Week 24.

    Time frame: Baseline to week 24

  2. Percentage of participants randomized to riliprubart with lasting response

    Lasting response is defined as a decrease of ≥1 point in adjusted INCAT disability score at week 48 versus baseline.

    Time frame: Baseline to week 48

  3. Percentage of participants randomized to placebo who experience a response

    A response is defined as a decrease of ≥1 point in adjusted INCAT disability score at Week 48 versus week 24.

    Time frame: Week 24 to week 48

Secondary outcomes

  1. Change from baseline in Inflammatory Raschbuilt Overall Disability Scale (IRODS) score

    Time frame: Baseline to week 24

  2. Change from baseline in adjusted inflammatory neuropathy cause and treatment (INCAT) disability score

    Time frame: Baseline to week 24

  3. Change from baseline in grip strength (kilopascals; dominant hand)

    Time frame: Baseline to week 24

  4. Change from baseline in Medical Research Council Sum Score (MRC-SS)

    Time frame: Baseline to week 24

  5. Percentage of participants refractory to immunoglobulins experiencing a response

    A response is defined as a decrease of ≥1 point from baseline in adjusted INCAT disability score at Week 24

    Time frame: Baseline to week 24

  6. Change from baseline in the EuroQol 5 Dimension, 5-Level Health Scale (EQ-5D-5L)

    Time frame: Baseline to week 24

  7. Change from baseline in the Rasch-built modified fatigue severity scale (RT-FSS)

    Time frame: Baseline to week 24

  8. Number of participants with treatment emergent adverse events (TEAEs), including serious adverse events (SAEs) and adverse events of special interest (AESIs) for Part A

    Time frame: Baseline to week 24

  9. Incidence and titer of anti-riliprubart antibodies (ADA)

    Time frame: Baseline to week 24

  10. Number of participants with TEAEs, including Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs) for Part B

    Time frame: Week 24 to week 103

  11. Incidence and titer of anti-riliprubart antibodies

    Time frame: Week 24 to week 103

  12. Change from baseline in I RODS score

    Time frame: Baseline to week 48

  13. Change from baseline in adjusted INCAT score

    Time frame: Baseline to week 48

  14. Change from baseline in grip strength (kilopascals; dominant hand)

    Time frame: Baseline to week 48

  15. Change from baseline in MRC-SS

    Time frame: Baseline to week 48

  16. Change from baseline in EQ-5D-5L score

    Time frame: Baseline to week 48

  17. Change from baseline in RT-FSS

    Time frame: Baseline to week 48

  18. Percentage of participants randomized to riliprubart who experience a response at Week 48 without prior response in Part A (delayed response)

    A delayed response is defined as a decrease of ≥1 point in adjusted INCAT disability score at Week 48 versus baseline.

    Time frame: Baseline to week 48

07

Study locations

132 sites
  • Alabama Neurology Associates- Site Number : 8400019
    Homewood, Alabama 35209, United States
  • USC Norris Comprehensive Cancer Center- Site Number : 8400002
    Los Angeles, California 90033, United States
  • University of California Irvine - Manchester Pavilion- Site Number : 8400007
    Orange, California 92868, United States
  • IMMUNOe International Research Centers - Centennial- Site Number : 8400049
    Centennial, Colorado 80112, United States
  • Yale University School of Medicine- Site Number : 8400018
    New Haven, Connecticut 06510, United States
  • Nova Clinical Research - Bradenton- Site Number : 8400044
    Bradenton, Florida 34209, United States
  • Design Neuroscience Center- Site Number : 8400053
    Miami Lakes, Florida 33016, United States
  • NorthShore University Health System - Glenbrook Hospital- Site Number : 8400024
    Glenview, Illinois 60026, United States
  • University of Kansas Medical Center- Site Number : 8400010
    Kansas City, Kansas 66160, United States
  • NeuroMedical Clinic of Central Louisiana- Site Number : 8400031
    Alexandria, Louisiana 71301, United States
  • Ochsner Medical Center - Jefferson Highway- Site Number : 8400030
    New Orleans, Louisiana 70121, United States
  • Johns Hopkins Hospital- Site Number : 8400015
    Baltimore, Maryland 21287, United States
  • Massachusetts General Hospital- Site Number : 8400009
    Boston, Massachusetts 02114, United States
  • Henry Ford Hospital- Site Number : 8400025
    Detroit, Michigan 48202, United States
  • Michigan State University- Site Number : 8400038
    East Lansing, Michigan 48824, United States
  • Washington University School of Medicine - Siteman Cancer Center- Site Number : 8400037
    St Louis, Missouri 63110, United States
  • Profound Research- Site Number : 8400052
    Las Vegas, Nevada 89106, United States
  • Hospital for Special Surgery - Site Number : 8400041
    New York, New York 10021, United States
  • Columbia University Irving Medical Center- Site Number : 8400003
    New York, New York 10032, United States
  • Raleigh Neurology Associates- Site Number : 8400043
    Raleigh, North Carolina 27607, United States
  • University of Cincinnati Medical Center- Site Number : 8400020
    Cincinnati, Ohio 45219, United States
  • University Hospitals Cleveland Medical Center- Site Number : 8400033
    Cleveland, Ohio 44106, United States
  • Penn State Health Milton South Hershey Medical Center- Site Number : 8400042
    Hershey, Pennsylvania 17033, United States
  • Penn Medicine: University of Pennsylvania Health System- Site Number : 8400022
    Philadelphia, Pennsylvania 19104, United States
  • Austin Neuromuscular Center- Site Number : 8400040
    Austin, Texas 78756, United States
  • UTHealth - The University of Texas Health Sciences Center at Houston- Site Number : 8400050
    Houston, Texas 77054, United States
  • University of Vermont Medical Center- Site Number : 8400012
    Burlington, Vermont 05401, United States
  • University of Virginia- Site Number : 8400023
    Charlottesville, Virginia 22908, United States
  • Investigational Site Number : 0320001
    Buenos Aires, 1015, Argentina
  • Investigational Site Number : 0320002
    Buenos Aires, 1181, Argentina
  • Investigational Site Number : 0320003
    Buenos Aires, 1221, Argentina
  • Investigational Site Number : 0560001
    Leuven, 3000, Belgium
  • Centro de Diagnostico e Pesquisa da Osteoporose do Espirito Santo- Site Number : 0760012
    Vitória, Espírito Santo 29055-450, Brazil
  • Hospital Sao Rafael- Site Number : 0760011
    Salvador, Estado de Bahia 41253-190, Brazil
  • Freire Pesquisa Clínica - Belo Horizonte - Rua Piauí- Site Number : 0760016
    Belo Horizonte, Minas Gerais 30150-320, Brazil
  • Hospital Moinhos de Vento- Site Number : 0760003
    Porto Alegre, Rio Grande do Sul 90035-902, Brazil
  • Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto- Site Number : 0760007
    Ribeirão Preto, São Paulo 14049-900, Brazil
  • PSEG Centro de Pesquisa Clínica- Site Number : 0760009
    São Paulo, 04038-002, Brazil
  • Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo- Site Number : 0760017
    São Paulo, 05403-000, Brazil
  • Investigational Site Number : 1000002
    Blagoevgrad, 2700, Bulgaria
  • Investigational Site Number : 1000001
    Pleven, 5800, Bulgaria
  • Investigational Site Number : 1240001
    Québec, Quebec G1E 7G9, Canada
  • Investigational Site Number : 1520003
    Lo Barnechea, Reg Metropolitana de Santiago 7691236, Chile
  • Investigational Site Number : 1520002
    Santiago, Reg Metropolitana de Santiago 8207257, Chile
  • Investigational Site Number : 1520001
    Santiago, Reg Metropolitana de Santiago 8380456, Chile
  • Investigational Site Number : 1560013
    Beijing, 100034, China
  • Investigational Site Number : 1560010
    Beijing, 100050, China
  • Investigational Site Number : 1560005
    Beijing, 100053, China
  • Investigational Site Number : 1560016
    Beijing, 100730, China
  • Investigational Site Number : 1560009
    Changsha, 410008, China
  • Investigational Site Number : 1560011
    Chengdu, 610072, China
  • Investigational Site Number : 1560002
    Fuzhou, 350001, China
  • Investigational Site Number : 1560012
    Guangzhou, 510000, China
  • Investigational Site Number : 1560007
    Guangzhou, 510080, China
  • Investigational Site Number : 1560014
    Hangzhou, 310003, China
  • Investigational Site Number : 1560008
    Jinan, 250014, China
  • Investigational Site Number : 1560015
    Nanchang, 330006, China
  • Investigational Site Number : 1560001
    Shanghai, 200040, China
  • Investigational Site Number : 1560003
    Wuhan, 430030, China
  • Investigational Site Number : 1560006
    Wuhan, 430060, China
  • Investigational Site Number : 1560004
    Xi'an, 710038, China
  • Investigational Site Number : 2030004
    Brno, 625 00, Czechia
  • Investigational Site Number : 2030003
    Hradec Králové, 500 05, Czechia
  • Investigational Site Number : 2030002
    Pardubice, 532 03, Czechia
  • Investigational Site Number : 2080002
    Aarhus, 8200, Denmark
  • Investigational Site Number : 2080001
    Copenhagen, 2100, Denmark
  • Investigational Site Number : 2500001
    Le Kremlin-Bicêtre, 94270, France
  • Investigational Site Number : 2500003
    Lille, 59037, France
  • Investigational Site Number : 2500002
    Marseille, 13885, France
  • Investigational Site Number : 2500005
    Montpellier, 34295, France
  • Investigational Site Number : 2500004
    Paris, 75013, France
  • Investigational Site Number : 2760001
    Bad Homburg, 61348, Germany
  • Investigational Site Number : 2760004
    Berlin, 12163, Germany
  • Investigational Site Number : 2760007
    Bochum, 44791, Germany
  • Investigational Site Number : 2760005
    Essen, 45147, Germany
  • Investigational Site Number : 2760003
    Giessen, 35392, Germany
  • Investigational Site Number : 2760006
    Tübingen, 72076, Germany
  • Investigational Site Number : 3000002
    Athens, 124 62, Greece
  • Investigational Site Number : 3000003
    Larissa, 411 10, Greece
  • Investigational Site Number : 3000001
    Thessaloniki, 546 36, Greece
  • Investigational Site Number : 3800001
    Milan, Milano 20132, Italy
  • Investigational Site Number : 3800009
    Rozzano, Milano 20089, Italy
  • Investigational Site Number : 3800006
    Rome, Roma 00133, Italy
  • Investigational Site Number : 3800008
    Rome, Roma 00189, Italy
  • Investigational Site Number : 3800007
    Messina, 98125, Italy
  • Investigational Site Number : 3800003
    Palermo, 90127, Italy
  • Investigational Site Number : 3800005
    Pavia, 27100, Italy
  • Investigational Site Number : 3800004
    Pisa, 56126, Italy
  • Investigational Site Number : 3920006
    Sayama, Osaka 589-8511, Japan
  • Investigational Site Number : 3920005
    Kawagoe, Saitama 350-8550, Japan
  • Investigational Site Number : 3920014
    Yaizu, Shizuoka 425-8505, Japan
  • Investigational Site Number : 3920011
    Bunkyo-Ku, Tokyo 113-8510, Japan
  • Investigational Site Number : 3920008
    Kodaira, Tokyo 187-8551, Japan
  • Investigational Site Number : 3920001
    Chiba, 260-8677, Japan
  • Investigational Site Number : 3920003
    Fukuoka, 812-8582, Japan
  • Investigational Site Number : 3920009
    Saga, 849-0937, Japan
  • Investigational Site Number : 3920013
    Tokyo, 173-8605, Japan
  • Investigational Site Number : 4840003
    Guadalajara, Jalisco 44670, Mexico
  • Investigational Site Number : 4840005
    Culiacán, Sinaloa 80020, Mexico
  • Investigational Site Number : 4840002
    Veracruz, 91900, Mexico

Showing the first 100 of 132 sites across 24 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2024 to primary completion in Jun 2026, 22 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2024
First posted
Mar 4, 2024
StartActual
Jul 12, 2024
Primary completionActual
Jun 10, 2026
CompletionEst.
Oct 31, 2027
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06290128
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Mar 4, 2024
Start date
Jul 12, 2024
Primary completion
Jun 10, 2026
Completion
Oct 31, 2027 (estimated)
Last update
Aug 10, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Riliprubart

Start the discussion